Please assess the completion status of the following clinical trial:

Trial Title: LANK-2: Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients between 0 and 23 years of age with diagnosis of acute lymphoblastic leukemia, in second relapse situation, posttransplant relapse or refractary, or~2. Patients between 0 and 23 years of age with diagnosis of acute myeloblastic leukemia, relapsed or refractary. (Patient must meet inclusion criteria 1 or 2)~3. Lansky index \> 60%~4. Mild (\<2) functional organs alteration (hepatic, renal, respiratory) according to National Cancer Institute criteria (NCI CTCAE v4).~5. Left ventricular ejection fraction \> 39%~6. To grant informed consent in accordance with the current legal regulations.~7. Presence of a compatible haploidentical donor (father or mother or brother).~Exclusion Criteria:~1. Patients with history of bad therapeutical compliance~2. Patients not valid after psycho-social evaluation~3. Positive HIV serology

- Gender: ALL
- Minimum Age: None
- Maximum Age: 23 Years
- Healthy Volunteers: f

Study Arms:
- Activated natural killer cells (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).